Adicet Bio, Inc. announced the opening of enrollment for its Phase 1 clinical trial of ADI-001 targeting autoimmune diseases, with plans to report preliminary data in early 2025.
AI Assistant
ADICET BIO INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.